Integra Lifesciences: Strategic Manufacturing Shifts Amid Supply Constraints – A Hold Rating Perspective
Truist Raises Price Target on Integra LifeSciences Holdings to $32 From $25, Maintains Hold Rating
Integra Lifesciences Sell Rating Justified by Production Delays and Overvalued Stock
Integra Lifesciences Analyst Ratings
Morgan Stanley Raises Price Target on Integra LifeSciences to $27 From $24, Keeps Underweight Rating
Integra Lifesciences: Hold Rating Justified by Operational Struggles and Competitive Underperformance
Integra Lifesciences Analyst Ratings
Integra Lifesciences Analyst Ratings
Oppenheimer Cuts Integra to Perform, Cites Boston Plant Delays
Wells Fargo Downgrades Integra Lifesciences to Equal-Weight, Lowers Price Target to $25
Integra Lifesciences (IART) Was Downgraded to a Hold Rating at Oppenheimer
Integra Lifesciences Analyst Ratings
Integra Lifesciences Sell Rating Justified Amid Operational Delays and Market Skepticism
Integra Lifesciences: Hold Rating Amidst Facility Delays and Operational Uncertainties
Buy Rating for Integra Lifesciences Amid Favorable Medicare Policy Changes
Jefferies Sticks to Their Buy Rating for Integra Lifesciences (IART)
Integra Lifesciences Analyst Ratings
Citigroup Upgrades Integra LifeSciences to Neutral From Sell, Price Target Is $38
Integra Lifesciences Analyst Ratings
BTIG Sticks to Its Hold Rating for Integra Lifesciences (IART)